Research Peptides
TB-500
- Research classification
- Research Peptides
For laboratory research use only. Not for human or veterinary use.
Lot & quality
Lot-specific analytical documentation
No verified lot documentation is published for this compound yet. Results, laboratories and purity values are never shown without a source record for the exact lot.
View available lot-specific analytical documentationEnter lot number
Verification connects to the BioNex lot and COA records in a later phase — no results are returned yet
- 01
Lot Number
- 02
COA
- 03
HPLC
- 04
Mass Spectrometry
- 05
Purity
- 06
Laboratory
- 07
Testing Date
- 08
QR Verification
Research snapshot
Verified research records currently indexed by BioNex
- Publication records
- 77
- Registered clinical trials
- 1
- Human observational
- 3
- Preclinical
- 8
- Reviews
- 14
- Related evidence
- 67
- International records
- 1
- Years indexed
- 2007–2026
Categories are listed separately and must not be added together: publication records and registered trial records are different record types, and a single study may appear in more than one category.
Compound profile
Research overview
Curated research content has not yet been imported for this compound. No generated summary is shown in its place.
Classification
Research areas
- Extracellular Matrix Research
Targets
Mechanisms under investigation
Actin-binding motif of thymosin beta-4 (LKKTETQ)
Investigated/proposed mechanism
LKKTETQ is described in the beta-thymosin literature as the actin-binding motif of thymosin beta-4. Activity of the isolated fragment in humans is not established.
Source
Evidence
Evidence breakdown
Direct compound evidence
8
Publication records indexed as describing this compound directly.
Related evidence
67
Parent-molecule or fragment literature. Counted separately and never added to direct evidence.
Human research
- Human observational3
Records describing research in human participants.
Preclinical research
- Animal7
- In vitro1
Animal and laboratory records. Not human evidence.
Review literature
- Reviews14
Reviews summarise other work rather than reporting new results.
Related evidence
- Parent molecule / fragment / mechanistic context67
Parent molecule, fragment and mechanistic context records. These are NOT direct evidence for this compound.
Registered clinical trials
- Registered trial records1
Registration records a study, not a result. Trials are counted separately from publications.
Scientific identity
Compound identity
- Canonical scientific name
- Thymosin beta-4 fragment (Ac-LKKTETQ), also known as TB-500
- Molecular formula
- C38H68N10O14
- Molecular weight
- 889.0 g/mol
- CAS number
- 885340-08-9
- Sequence
- Ac-LKKTETQ
- Sequence length
- 7 residues
- PubChem CID
- 62707662
- UNII
- QHK6Z47GTG
- Research classification
- Research Peptides
Indexed literature describes: Identity data describe the acetylated heptapeptide fragment Ac-LKKTETQ (CAS 885340-08-9, PubChem CID 62707662), which is distinct from full-length thymosin beta-4 (43-residue parent protein).
These records describe the scientific entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.
Scientific data
- Compound
- TB-500
- Molecular formula
- C38H68N10O14
- Molecular weight
- 889.0 g/mol
- CAS number
- 885340-08-9
- Peptide sequence
- Ac-LKKTETQ
- Research classification
- Research Peptides
Published research
Representative recent records
Verified records currently indexed by BioNex
Loading records
Regulatory
Regulatory records by jurisdiction
Regulatory records are held separately from research evidence. Authorisation or regulatory activity in one jurisdiction never implies the same status in another.
Thymosin beta-4 fragment (LKKTETQ), also known as TB-500, listed in FDA Category 2 for compounding
U.S. Food and Drug Administration (FDA) · FDA bulk drug substances nominated for compounding — Category 2 (substances that may present significant safety risks). Not an approval, not a clinical-trial determination, not a general prohibition, and not an efficacy judgement. · 2026-04-22
Not an approval determination
Primary source
Scientific identity records describe the entity reported in the literature. Lot-specific analytical documentation is available through BioNex Quality Verification when provided for the applicable lot.
BioNex Research Intelligence summarizes and organizes scientific literature for research and educational purposes. Inclusion of a publication, clinical trial, or regulatory record does not constitute endorsement, clinical guidance, or evidence of safety or efficacy for human use.